Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
| Page | ||
|---|---|---|
| Special Note Regarding Forward Looking Statements | 4 | |
| Summary of Selected Risks associated with our Business | 6 | |
| PART I. | 9 | |
| Item 1. | Business | 9 |
| Item 1A. | Risk Factors | 20 |
| Item 1B. | Unresolved Staff Comments | 35 |
| Item 1C | Cybersecurity | 35 |
| Item 2. | Properties | 36 |
| Item 3. | Legal Proceedings | 36 |
| Item 4. | Mine Safety Disclosures | 36 |
| Part II | 36 | |
| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 36 |
| Item 6. | Reserved | 37 |
| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations Overview | 37 |
| Item 7A. | Quantitative and Qualitative Disclosure About Market Risk | 42 |
| Item 8. | Financial Statements and Supplementary Data | 43 |
| Index to Financial Statements | 43 | |
| Report of Independent Registered Public Accounting Firm | 44 | |
| Consolidated Balance Sheets | 46 | |
| Consolidated Statements of Operations | 47 | |
| Consolidated Statements of Cash Flows | 48 | |
| Consolidated Statement of Stockholders' Equity (Deficit) | 49 | |
| Notes to Consolidated Financial Statements | 50 | |
| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 61 |
| Item 9A. | Controls and Procedures | 61 |
| Item 9B. | Other Information | 62 |
| Part III | 62 | |
| Item 10. | Directors, Executive Officers and Corporate Governance | 62 |
| Item 11. | Executive Compensation | 70 |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 78 |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence | 79 |
| Item 14. | Principal Accounting Fees and Services | 81 |
| Part IV | 82 | |
| Item 15. | Exhibits, Financial Statement Schedules | 82 |
| SIGNATURES | 86 | |
On June 14, 2024, the Company filed a Certificate of Amendment to the Company’s restated certificate of incorporation, as amended, with the Secretary of State of the State of Delaware to effect a 1-for-8 reverse stock split of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Reverse Stock
Split”) which became effective as of June 14, 2024. All historical share and per share amounts reflected throughout this report have been adjusted to reflect the Reverse Stock Split.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.